Nuclera
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Benchtop protein prototyping platform
Integrated benchtop system for cell-free protein synthesis, digital microfluidics, and software-driven automation to accelerate the design, screening, and purification of proteins, including membrane proteins.
Benchtop protein prototyping platform
Integrated benchtop system for cell-free protein synthesis, digital microfluidics, and software-driven automation to accelerate the design, screening, and purification of proteins, including membrane proteins.
Services
Provision of rapid, high-throughput protein expression and purification services through contract research organizations utilizing automated benchtop systems.
Provision of rapid, high-throughput protein expression and purification services through contract research organizations utilizing automated benchtop systems.
Expertise Areas
- Protein expression and purification optimization
- Membrane protein production and stabilization
- High-throughput screening for protein constructs and conditions
- Digital microfluidics for biotechnology
Key Technologies
- Cell-free protein synthesis
- Digital microfluidics
- Lab-on-a-chip
- Automated liquid handling
News & Updates
Webinar featuring a rapid, scalable workflow for membrane protein expression using digital microfluidics, held on November 4, 2025.
Participation at PEGs Summit in Lisbon, Portugal, to showcase cell-free protein expression technologies.
Attendance at Drug Discovery World London to demonstrate protein expression workflow advances.
Announcement of collaboration to integrate rapid protein production and characterization workflows, reducing time from expression to analysis.
Expanded distribution network and support infrastructure in Asia-Pacific and Middle East markets.
Launch of a new workflow supporting production and stabilization of membrane proteins for drug discovery and structural biology.
Webinar featuring a rapid, scalable workflow for membrane protein expression using digital microfluidics, held on November 4, 2025.
Participation at PEGs Summit in Lisbon, Portugal, to showcase cell-free protein expression technologies.
Attendance at Drug Discovery World London to demonstrate protein expression workflow advances.
Announcement of collaboration to integrate rapid protein production and characterization workflows, reducing time from expression to analysis.
Expanded distribution network and support infrastructure in Asia-Pacific and Middle East markets.
Launch of a new workflow supporting production and stabilization of membrane proteins for drug discovery and structural biology.